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A bacterium cannot be clinically categorized as 
susceptible to an antibiotic in one hospital or country 
and resistant in another. The need for standardization 
of in vitro antibiotic susceptibility tests (the antibio- 
gramme) appeared very soon, in the early 1950s. The 
World Health Organization convened in Geneva a first 
Expert Committee on Antibiotics in 1959 and a second 
in 1961 (WHO Technical Report Series 1959 No. 710 
and 1961 No. 210). It immediately appeared that the 
Committee had to work in two fields: the methods and 
the interpretation of the data. However, it was also clear 
that the need for reference methods was a priority. In 
fact, the efforts devoted to define all the details of a 
reference method at WHO meetings and later were 
continuous until 1970. The problem of the clinical 
interpretation (determination of the breakpoints) 
seemed too controversial at the international level, and 
the second WHO Committee suggested that this area 
should be the concern of a ‘National Authority’. 
Consequently, the role of a National Committee is 
mainly in the field of interpretation. Nevertheless, in 
the past 20 years an important number of new 
techniques, devices and machines (more or less 
automated) have been proposed to simplify and 
accelerate the work of clinical laboratories. All these 
approaches cannot be accepted without a control. A 
national network of medical microbiology laboratories 
specializing in antibiotic evaluation has to play a role in 
this control under the supervision of a National 
Reference Center for Antibiotics. Evaluation of a new 
technique is not always easy. Some methods provide 
values that can be directly compared with the MIC 
determined by the reference methods defined at the 
international level. However, many others, automated 
or not, are intended to directly characterize clinically 
the strains studied. In certain instances, it is possible, 
using the basic principle of the proposed new 
technique, to perform a quantitative study in an 
attempt to correlate its results with those of the 
reference method. When this is not possible, the study 
of reference strains from the National Reference 
Center may provide a good approximation to decide if 
the technique is valuable or not, or has to be adjusted. 
Many of these evaluations can be performed in 
agreement with the manufacturer, who provides 
supplementary information and materials. The results 
are often confidential or not sufficient to justify a 
scientific publication. Since the clinical laboratories of 
a country need to be informed of the exact value of a 
new technique, the role of the National Committee is 
important in discussion and in informing all the 
medical microbiology laboratories. Such a Committee 
is even worthwhile for the adequate use of the new 
methods nationwide. 
As already pointed out, the major role of a 
National Committee is to decide on values of the 
breakpoints that delineate the clinical categories. The 
subject is controversial, as pointed out by Garrod at the 
first W H O  meeting, because of the two definitions of 
resistance. The first is related to the pharmacologic data 
on the antibiotic concentrations achieved at the site of 
infection. The second is related to genetic alterations of 
the bacteria which, consequently, allow growth in the 
presence of an antibiotic concentration higher than that 
inhibiting the so-called susceptible bacteria. This 
latter notion has been exemplified since 1947 by 
the p-lactamase-producing strains of staphylococci. 
Depending on the relative importance attributed to 
one or the other factor, the value of the breakpoint 
relies heavily on judgment and experience. It is 
important to specify the various factors that have to be 
taken into account at a national level to adopt a 
particular breakpoint. All antibiotics are not widely 
used at the same time in all countries, in particular the 
recent molecules. The need for breakpoints is especially 
urgent when a new drug appears on the market. The 
breakpoints cannot be selected irrespective of those 
already chosen for the other members of the antibiotic 
family. A National Committee has to balance the 
intrinsic activity and the pharmacology of the new drug 
comparatively with the other members of the same 
family. Under certain circumstances, a particular 
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breakpoint has to be chosen in case of special dosage, 
route, site of infection, or groups of bacteria. These 
values vary from one country to another depending on 
the therapeutic habits and predominant infections. All 
these local problems have to be taken into account by 
a National Committee. A new resistance character can 
emerge and be widespread in one country, and it is 
important to provide information to the clinical 
laboratories in order to detect it. In the past 20 years, 
a considerable amount of work has been devoted to the 
study of antibiotic-inactivating enzymes, structural 
modifications ofthe targets, and their genetic basis. The 
‘analytical approach’ or ‘interpretive reading’ of the 
resistance characters correlated with these modifica- 
tions is intended to define them by means of their 
phenotypic behavior or by molecular studies (probes or 
polymerase chain reaction (PCR), for example). Some 
of these new characters lead to low-level or inter- 
mediate categories of resistance. Their clinical 
consequences may be questionable. Modification of 
breakpoints of an antibiotic family based on the 
existence of this type of resistance mechanisms needs 
collaborative in vitro, experimental or clinical studies 
that can be undertaken by a group under the authority 
of a National Committee. 
To face all these problems, the Comitk de /’Anti- 
biogramme de la Socie‘tk Francaise de Microbiologie was 
created in 1980. It included 20 members: bacterio- 
logists specializing in antibiotics, pharmacologists and 
clinicians. Collaborative studies were performed in the 
laboratories of the group members and the results 
reported in an annual meeting where modifications or 
new breakpoints were discussed and accepted. A 
communiquk reviewing all the breakpoints is annually 
published in the abstract book of the Interdisciplinary 
Meeting on Anti-infectious Chemotherapy, which 
takes place every December in Paris, and also with the 
proceedings of the meeting that are published in a 
special issue of the journal Puthologie et Biologie. 
Representatives of a National Committee must be 
natural members of regional (European) or inter- 
national groups trying to establish common values for 
interpretation of in vitro susceptibility testing methods. 
An excellent example of the methodology to achieve a 
broad agreement is the International Collaborative 
Study working in the field of reference methods. From 
1961 to 1968, a working group of 20 directors of 
laboratories from 11 countries engaged in susceptibility 
testing prepared 40 reports which were exchanged and 
discussed on numerous occasions in Stockholm, 
Geneva, and at international congresses. The final draft, 
written by Hans M. Ericsson and John C. Sherris, was 
sufficiently documented to be widely accepted. In the 
field of interpretation, the same type of organization 
exists only at the national level in certain countries. 
However, committees, governmental offices or manu- 
facturers propose breakpoints without any explanation 
of the criteria for their choice. It seems difficult to 
establish common values without a collaborative 
organization able to remedy this lack of information. 
Justification of choices and documents must be 
exchanged before any discussion. Administrative regu- 
lations cannot be imposed without documented 
discussion by all the scientific people engaged in the 
field of antibiotics. 
